Company intelligence / Profile preview

Precedo Pharmaceuticals

Ownership: Private
Development stage: Other

Overview

Precedo Pharmaceuticals is a China-based biotech company focused on developing novel culture media for organoid and epithelial cell cultures, particularly in oncology, as well as small molecule dual inhibitors targeting EGFR and ALK for non-small cell lung cancer. The company appears to be in the pre-clinical stage with no disclosed clinical trial results.

Therapeutic areas: Oncology
Modalities: Small moleculeCulture medium (for organoid and cell culture applications)
Industry: Biotech

Partnerships

Chinese Academy of Sciences (CAS) support

Beyond the preview

Go deeper on Precedo Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Precedo Pharmaceuticals.

Explore the full profile